Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
PCSK9 Inhibitors: Evidence Summary
Evidence summary for PCSK9 Inhibitors across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to PCSK9 Inhibitors overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| LDL cholesterol reduction | Tier A | 50 | Consistent 50-60% LDL-C reduction across 50+ RCTs |
| Cardiovascular event prevention | Tier A | 3 | FOURIER and ODYSSEY OUTCOMES demonstrated 15% MACE reduction |
| Familial hypercholesterolemia | Tier A | 10 | FDA-approved indication with robust evidence |
References (4)
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease — Sabatine MS, Giugliano RP, Keech AC, et al. . New England Journal of Medicine (2017) PMID: 28304224
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome — Schwartz GG, Steg PG, Szarek M, et al. . New England Journal of Medicine (2018) PMID: 30403574
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol — Ray KK, Wright RS, Kallend D, et al. . New England Journal of Medicine (2020) PMID: 32187462
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events — Robinson JG, Farnier M, Krempf M, et al. . New England Journal of Medicine (2015) PMID: 25773378